Cost Effectiveness of Imatinib Compared with Interferon- or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia

Author： Dalziel Kim Round Ali Garside Ruth Stein Ken

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.5, 2005-01, pp. : 515-526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-α Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

By Reed Shelby D. Anstrom Kevin J. Li Yanhong Schulman Kevin A.

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite

Nilotinib: In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

By Garnock-Jones Karly P.

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 8, 2005-08 ,pp. : 1063-1066

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J Xu G Yu S He L Guo L

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite